BOSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced a proposed public offering of 150millionofitscommonstock.AllsecuritiesintheofferingwillbeofferedbyRhythm.Inaddition,Rhythmintendstogranttheunderwritersa30−dayoptiontopurchaseuptoanadditional22.5 million of shares of comm ...